Report on the 4th International Conference on the Adjuvant Therapy of Malignant Melanoma held at the Royal College of Physicians, London, UK, 15-16 March 2002.
Retsas
S
S
Melanoma Unit, Hammersmith Hospital NHS Trust, Charing Cross Campus, London W6 8RF, UK. sretsas@msn.com
Falkson
C
C
Spitler
L
L
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D007167:Immunotherapy; D016219:Immunotherapy, Adoptive; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D021701:Sentinel Lymph Node Biopsy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D016898:Interferon-alpha